Translational Development Acquisition (TDACW) Non Operating Investment Income (2024 - 2026)
Translational Development Acquisition's (TDACW) quarterly Non Operating Investment Income came in at -$36138.0 in Q2 2026, down 128.83% quarter-over-quarter from $125346.0 in Q4 2024.
Powered by 
Analysis
Translational Development Acquisition (TDACW) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Translational Development Acquisition (TDACW) has reported Non Operating Investment Income for 2 consecutive years, with -$36138.0 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Evercore | 11.52 Bn | 9.43 Bn | 975.67 Mn | - |
| 2 | Jefferies Financial | 11.24 Bn | -4.17 Bn | 3.09 Bn | - |
| 3 | Houlihan Lokey | 9.53 Bn | 8.45 Bn | - | - |
| 4 | Cluster Group Holdings | 8.00 Bn | 8.00 Bn | - | - |
| 5 | PJT Partners | 6.94 Bn | 6.99 Bn | 481.98 Mn | - |
| 6 | Moelis | 6.06 Bn | 5.99 Bn | - | - |
| 7 | Piper Sandler Companies | 5.20 Bn | 5.09 Bn | - | - |
| 8 | Lazard | 4.97 Bn | 3.99 Bn | - | - |
| 9 | BRBI BR Partners | 3.44 Bn | 3.32 Bn | 16.77 Mn | - |
| 10 | Translational Development Acquisition | 52.67 Mn | 52.58 Mn | - | -36,138.00 |